SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla informs about informs about company updates

20 Jul 2019 Evaluate

Cipla has informed that the United States Food and Drug Administration (USFDA) conducted a routine cGMP inspection at its API manufacturing facility in Virgonangar, Bengaluru, from 15th June, 2019 to 19th June, 2019. The inspection ended with 7 observations, none of which were repeat or related to data integrity. The Company will respond to the agency within the stipulated timeline.

The above information is a part of company’s filings submitted to BSE.

Cipla Share Price

1347.70 -15.15 (-1.11%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×